Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. - Banchereau,J.; Ueno,H.; Dhodapkar,M.; Connolly,J.; Finholt,JP.; Klechevsky,E. (J Immunother (1997), 2005)